Search

Your search keyword '"Jagasia, Madan"' showing total 14 results
Start Over Author "Jagasia, Madan" Journal bone marrow transplantation
14 results on '"Jagasia, Madan"'

1. Lymphoid and myeloid immune cell reconstitution after nicotinamide-expanded cord blood transplantation

Author

de Koning, Coco, primary, Tao, Weiyang, additional, Lacna, Amelia, additional, van Veghel, Karin, additional, Horwitz, Mitchell E., additional, Sanz, Guillermo, additional, Jagasia, Madan H., additional, Wagner, John E., additional, Stiff, Patrick J., additional, Hanna, Rabi, additional, Cilloni, Daniela, additional, Valcárcel, David, additional, Peled, Tony, additional, Galamidi Cohen, Einat, additional, Goshen, Uri, additional, Pandit, Aridaman, additional, Lindemans, Caroline A., additional, Jan Boelens, Jaap, additional, and Nierkens, Stefan, additional

Published
2021
Full Text
View/download PDF

3. Minimal residual disease negativity and lenalidomide maintenance therapy are associated with superior survival outcomes in multiple myeloma

Author

Patel, Dilan A., primary, Gopalakrishnan, Ragisha, additional, Engelhardt, Brian G., additional, McArthur, Evonne, additional, Sengsayadeth, Salyka, additional, Culos, Katie A., additional, Byrne, Michael, additional, Goodman, Stacey, additional, Savani, Bipin N., additional, Chinratanalab, Wichai, additional, Jagasia, Madan, additional, Mosse, Claudio A., additional, Cornell, Robert F., additional, and Kassim, Adetola A., additional

Published
2020
Full Text
View/download PDF

7. Prospective trial of minimal residual disease assessment by multiparametric flow cytometry for multiple myeloma in the era of bortezomib-based chemotherapy

Author

Clark, C. Amos, primary, Mosse, Claudio A., additional, Chen, Heidi, additional, Byrne, Michael, additional, Chinratanalab, Wichai, additional, Engelhardt, Brian G., additional, Goodman, Stacey A., additional, Harrell, Shelton L., additional, Kassim, Adetola A., additional, Savani, Bipin N., additional, Sengsayadeth, Salyka, additional, Jagasia, Madan, additional, and Cornell, R. Frank, additional

Published
2018
Full Text
View/download PDF

9. Lenalidomide vs bortezomib maintenance choice post-autologous hematopoietic cell transplantation for multiple myeloma

Author

Huang, Jennifer, primary, Phillips, Sharon, additional, Byrne, Michael, additional, Chinratanalab, Wichai, additional, Engelhardt, Brian G., additional, Goodman, Stacey A., additional, Harrell, Shelton L., additional, Jagasia, Madan, additional, Kassim, Adetola, additional, Rawling, Kyle T., additional, Savani, Bipin N., additional, Sengsayadeth, Salyka, additional, and Cornell, R. Frank, additional

Published
2018
Full Text
View/download PDF

10. Outcomes of a novel rituximab-based non-myeloablative conditioning regimen for hematopoietic cell transplantation in severe aplastic anemia

Author

Gatwood, Katie S., primary, Culos, Kathryn A., additional, Binari, Laura A., additional, Engelhardt, Brian G., additional, Kassim, Adetola, additional, Byrne, Michael T., additional, Goodman, Stacey A., additional, Chinratanalab, Wichai, additional, Sengsayadeth, Salyka M., additional, Greer, John P., additional, Jagasia, Madan, additional, and Savani, Bipin N., additional

Published
2018
Full Text
View/download PDF

11. Six Month Freedom from Treatment Failure is an Important Endpoint for Acute Graft-Versus-Host Disease Clinical Trials

Author

Sengsayadeth, Salyka, Savani, Bipin N., Jagasia, Madan, Goodman, Stacey, Greer, John P., Chen, Heidi, Chinratanalab, Wichai, Kassim, Adetola A., and Engelhardt, Brian G.

Subjects
Adult, Male, clinical trials, Transplantation Conditioning, acute graft versus host disease, Hematopoietic Stem Cell Transplantation, Graft vs Host Disease, Middle Aged, Survival Analysis, Article, Treatment Outcome, Acute Disease, Humans, Transplantation, Homologous, Female, Treatment Failure, hematopoietic stem cell transplant, Aged
Abstract

We studied the American Society for Blood and Marrow Transplantation (ASBMT) 6-month (m) freedom from treatment failure (FFTF) as a predictor of survival for patients with acute GVHD (aGVHD) requiring treatment. Adult patients undergoing allogeneic hematopoietic cell transplant (HCT) from February 2007 to March 2009 who were enrolled in a prospective biomarker clinical trial and developed aGVHD requiring systemic corticosteroids by day +100 were included (N=44). Six-month FFTF was defined as per the ASBMT guidelines (absence of death, malignancy relapse/progression or systemic immunosuppression change within 6 months of starting steroids and before chronic GVHD development). aGVHD was treated with systemic corticosteroids in 44 patients. Day 28 response after steroid initiation (complete response+very good partial response+partial response) occurred in 38 (87%) patients, but only 28 (64%) HCT recipients met the 6-m FFTF end point. Day 28 response predicted 6-m FFTF. Achieving 6-m FFTF was associated with improved 2-year (y) OS (81% vs 48%; P=0.03) and decreased 2-y non-relapse mortality (8% vs 49%; P=0.01). In multivariate analysis, 6-m FFTF continued to predict improved OS (hazard ratio, 0.27; P=0.03). The 6-m FFTF end point measures fixed outcomes, predicts long-term therapeutic success and could be less prone to measurement error than aGVHD clinical response at day 28.

Published
2013

Catalog

Books, media, physical & digital resources
See catalog results